23 research outputs found
Hepatitis C Therapy in Renal Patients: Who, How, When?
<p><u>Article
full text</u></p>
<p>The full text of this
article can be found at <b><u>https://link.springer.com/article/10.1007/s40121-016-0116-z</u></b></p><p><b><u><br></u></b></p>
<p><u>Provide
enhanced content for this article</u></p>
<p>If you are an author
of this publication and would like to provide additional enhanced content for
your article then please contact <a href="http://www.medengine.com/Redeem/âmailto:[email protected]â"><b>[email protected]</b></a>.</p>
<p>The journal offers a
range of additional features designed to increase visibility and readership.
All features will be thoroughly peer reviewed to ensure the content is of the
highest scientific standard and all features are marked as ‘peer reviewed’ to
ensure readers are aware that the content has been reviewed to the same level
as the articles they are being presented alongside. Moreover, all sponsorship
and disclosure information is included to provide complete transparency and
adherence to good publication practices. This ensures that however the content
is reached the reader has a full understanding of its origin. No fees are
charged for hosting additional open access content.</p>
<p>Other enhanced
features include, but are not limited to:</p>
<ul>
<li>Slide decks</li>
<li>Videos and animations</li>
<li>Audio abstracts</li>
<li>Audio slides</li>
</ul
Additional file 2: of Awareness, discussion and non-prescribed use of HIV pre-exposure prophylaxis among persons living with HIV/AIDS in Italy: a Nationwide, cross-sectional study among patients on antiretrovirals and their treating HIV physicians
a: PrEPventHIV_patients_1405. Original database (Patients). b: PrEPventHIV_physicians_87. Original database (HIV specialists). (ZIP 177âkb
Safety in the cohort treated by Peg-IFN-based therapy.
<p>Safety in the cohort treated by Peg-IFN-based therapy.</p
Characteristics and follow-up of the patients with HCV infection and B-NHL treated by direct-acting antiviral drugs (DAAs).
<p>Marginal zone lymphomas (MZLs); Diffuse large B-cell lymphomas (DLBCLs).</p
Sustained virologic response of the patients from the cohort treated by Peg-IFN-based therapy, * p< 0.02.
<p>First generation of protease inhibitors (PI1s). A: global sustained virologic response. B: sustained virologic response according to HCV genotype.</p
Haematological response of the patients from the B-NHL group treated by Peg-IFN-based therapy with or without sustained virologic response, * p = 0.02.
<p>Haematological response of the patients from the B-NHL group treated by Peg-IFN-based therapy with or without sustained virologic response, * p = 0.02.</p
Predictive factors associated with sustained virologic response in the cohort treated by Peg-IFN-based therapy.
<p>Predictive factors associated with sustained virologic response in the cohort treated by Peg-IFN-based therapy.</p
Overall survival of the patients with B-NHL and controls.
<p>Overall survival of the patients with B-NHL and controls.</p
Flowchart.
<p>Peg-interferon-alpha (Peg-IFN), B-cell non-Hodgkin lymphoma (B-NHL) First generation of protease inhibitors (PI1s), Direct-acting antiviral drugs (DAAs).</p
Characteristics of the patients treated by Peg-IFN-based therapy.
<p>Characteristics of the patients treated by Peg-IFN-based therapy.</p